European Foundation for the Study of Diabetes
OrganisationROR
Trials
Collaborator, Phase 4, Completed, 56 people, 25 Mar 2015
Phase 1/2, Completed, 30 people, 12 Jul 2010
Awards made
EFSD/Novo Nordisk Foundation Future Leaders Award, Decoding GLP-1 Receptor Agonist Resistance: From Evolution to Mechanisms, EFSD-novo-nordisk-foundation-future-leaders-a-2026-elisa-araldi, 2026, 1 Jan 2026
EFSD/Novo Nordisk Foundation Future Leaders Award, Decoding GLP-1 Receptor Agonist Resistance: From Evolution to Mechanisms, EFSD-novo-nordisk-foundation-future-leaders-a-2026-elisa-araldi, 2026, 1 Jan 2026
EFSD/Lilly Young Investigator Research Award Programme, Antigen-presenting adipocytes as a novel component of visceral adipose tissue inflammation after menopause, EFSD-lilly-young-investigator-2025-carla-horvath, 2025, 1 Jan 2025
EFSD/Lilly Young Investigator Research Award Programme, Antigen-presenting adipocytes as a novel component of visceral adipose tissue inflammation after menopause, EFSD-lilly-young-investigator-2025-carla-horvath, 2025, 1 Jan 2025
EFSD/JDS Reciprocal Travel Fellowship Programme, Spatial Signature of Senescent Cells in Muscle Aging and Modulation by Nutritional Intervention, EFSD-jds-reciprocal-2025-hirotaka-araki, 2025, 1 Jan 2025
EFSD/JDS Reciprocal Travel Fellowship Programme, Spatial Signature of Senescent Cells in Muscle Aging and Modulation by Nutritional Intervention, EFSD-jds-reciprocal-2025-hirotaka-araki, 2025, 1 Jan 2025
EFSD/Lilly European Diabetes Research Programme, GLP-1 is safe from hypoglycaemia, but why?, EFSD-lilly-euro-diab-research-2023-jens-juul-holst, 2023, 1 Jan 2023
EFSD/Lilly European Diabetes Research Programme, GLP-1 is safe from hypoglycaemia, but why?, EFSD-lilly-euro-diab-research-2023-jens-juul-holst, 2023, 1 Jan 2023
EFSD/Novo Nordisk A/S Programme for Diabetes Research in Europe, Fructose is central in diabetic kidney disease and mediates the protective effects of SGLT2 inhibitors, EFSD-nn-as-diab-research-europe-2022-gil-leibowitz, 2022, 1 Jan 2022
EFSD/Novo Nordisk A/S Programme for Diabetes Research in Europe, Fructose is central in diabetic kidney disease and mediates the protective effects of SGLT2 inhibitors, EFSD-nn-as-diab-research-europe-2022-gil-leibowitz, 2022, 1 Jan 2022
EFSD Rising Star Fellowship Programme supported by Novo Nordisk, Individual-level cardiovascular and heart failure risk stratification to inform precision SGLT2-inhibitor treatment, EFSD-nn-rising-star-2022-john-dennis, 2022, 1 Jan 2022
EFSD Rising Star Fellowship Programme supported by Novo Nordisk, Individual-level cardiovascular and heart failure risk stratification to inform precision SGLT2-inhibitor treatment, EFSD-nn-rising-star-2022-john-dennis, 2022, 1 Jan 2022
EFSD/Boehringer Ingelheim European Research Programme on “Multi-System Challenges in Diabetes”, Rejuvenating mitochondria to alleviate premature senescence and multimorbidity in diabetes, EFSD-bi-multi-system-challenges-2021-jose-romero, 2021, 1 Jan 2021
EFSD/Boehringer Ingelheim European Research Programme on “Multi-System Challenges in Diabetes”, Rejuvenating mitochondria to alleviate premature senescence and multimorbidity in diabetes, EFSD-bi-multi-system-challenges-2021-jose-romero, 2021, 1 Jan 2021
EFSD/Novo Nordisk A/S Programme for Diabetes Research in Europe, Cell regeneration in the human kidney in health and diabetic kidney disease, EFSD-nn-as-diab-research-europe-2021-kirsty-spalding, 2021, 1 Jan 2021
EFSD/Novo Nordisk A/S Programme for Diabetes Research in Europe, Cell regeneration in the human kidney in health and diabetic kidney disease, EFSD-nn-as-diab-research-europe-2021-kirsty-spalding, 2021, 1 Jan 2021
EFSD/Lilly Young Investigator Research Award Programme, Targeting cellular senescence in individuals with type 2 diabetes with Non-Alcoholic Fatty Liver disease, EFSD-lilly-young-investigator-2021-abraham-meijnikman, 2021, 1 Jan 2021
EFSD/Lilly Young Investigator Research Award Programme, Targeting cellular senescence in individuals with type 2 diabetes with Non-Alcoholic Fatty Liver disease, EFSD-lilly-young-investigator-2021-abraham-meijnikman, 2021, 1 Jan 2021
EFSD/Lilly EXPLORING AND APPLYING NEW STRATEGIES IN DIABETES (EXPAND) Programme, Exploring time-restricted eating as a strategy to prevent weight gain in South Africans (TESSA), EFSD-lilly-expand-2020-kristine-faerch, 2020, 1 Jan 2020
Steno Diabetes Center Copenhagen
EFSD/Lilly EXPLORING AND APPLYING NEW STRATEGIES IN DIABETES (EXPAND) Programme, Exploring time-restricted eating as a strategy to prevent weight gain in South Africans (TESSA), EFSD-lilly-expand-2020-kristine-faerch, 2020, 1 Jan 2020
Sources: openalex.org
Funded papers
Sources: api.crossref.org